BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than ...

The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the ...

No writing assistance was utilized in the production of this manuscript. Plasmacytoid dendritic cells (pDCs) are specialized APCs. Compared with other APCs, pDCs express a high level of TLR9 and ...

Researchers have uncovered critical mechanisms linked to metabolic insufficiencies that underlie plasmacytoid dendritic cell ...

In one study, a team of researchers led by Franck Barrat, Ph.D., found that two genetic receptors called TLR7 and TLR8, which are present on the X chromosome, are important drivers for the activation ...

An expert discusses how blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy derived from ...

Zúñiga believes that interventions that target LDHB or related metabolic pathways could be explored as a way to counteract ...

An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment, leveraging its CD123-targeted efficacy per 0114 trial ...

As part of the innate immune system, dendritic cells are in the body's first line of defense against infections. They detect pathogens and coordinate the immune response. An international team led ...